NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 132 filers reported holding NOVOCURE LTD in Q1 2018. The put-call ratio across all filers is 0.13 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $401,000 | -90.9% | 3,600 | -93.9% | 0.12% | -68.9% |
| Q3 2019 | $4,414,000 | +34.7% | 59,024 | +13.9% | 0.38% | +47.9% |
| Q2 2019 | $3,277,000 | +30.2% | 51,824 | -35.6% | 0.26% | +41.2% |
| Q2 2018 | $2,517,000 | -16.7% | 80,423 | -42.0% | 0.18% | -19.8% |
| Q1 2018 | $3,022,000 | – | 138,620 | – | 0.23% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 470,884 | $39,681,000 | 20.12% |
| HARTLINE INVESTMENT CORP/ | 330,672 | $27,866,000 | 5.97% |
| MORGAN JESS S & CO INC | 52,889 | $4,457,000 | 4.37% |
| Darsana Capital Partners LP | 1,350,000 | $113,765,000 | 3.88% |
| Rhenman & Partners Asset Management AB | 350,000 | $29,495,000 | 3.23% |
| COURAGE CAPITAL MANAGEMENT LLC | 10,000 | $843,000 | 2.55% |
| Taylor Frigon Capital Management LLC | 38,073 | $3,208,000 | 2.21% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 35,500 | $2,991,000 | 1.08% |
| Granite Investment Partners, LLC | 261,315 | $22,021,000 | 1.04% |
| Nicholas Investment Partners, LP | 85,835 | $7,233,000 | 0.74% |